A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Swedish Orphan Biovitrum
Study ID
NCT06782373
Phase
PHASE2
Status
Recruiting

Conditions

  • VEXAS
  • VEXAS Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pacritinib — DRUG
    Supplied in hard capsules.
  • Placebo — DRUG
    Supplied in hard capsules.

Study Details

This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. 78 participants will be enrolled, randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. Randomization will be stratified by prescribed GC dose on the day of randomization.

Key Dates

Start date
May 28, 2025
Status verified
Mar 2026
Primary completion
Dec 30, 2026
Completion
May 22, 2028

Study Design

Enrollment
78 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Pacritinib
    To receive oral administration of pacritinib dose A for up to 24 weeks.
  • Experimental: Pacritinib + placebo
    To receive oral administration of pacritinib dose B plus placebo for up to 24 weeks
  • Placebo Comparator: Placebo
    To receive oral administration of placebo for up to 24 weeks.

Primary Outcome Measure

Overall Clinical Response (OCR), defined as achieving Clinical Response or better at any time during the double-blind treatment period. [ Time Frame: up to End of Week 24 ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
Mayo Clinic - ScottsdaleScottsdaleArizona85259-
Dana Farber Cancer InstituteBostonMassachusetts02215-
Mayo Clinic - RochesterRochesterMinnesota55905-
NYU Langone HealthNew YorkNew York10016-
Cleveland Clinic - ClevelandClevelandOhio44195-
The James Cancer Hospital and Solove Research InstituteColumbusOhio43210-
UT MD Anderson Cancer CenterHoustonTexas77030-
University of Utah HealthcareSalt Lake CityUtah84132-
Fred Hutchinson Cancer CenterSeattleWashington98109-

Find similar trials in Scottsdale, AZ

Related Studies